INVESTOR FACT SHEET

$18.00/ $13.1552 Week HigH/LOW

$314M MARkeT CAP

21MOUTSTANDiNg

SHAReS

76,325 3-MONTHD

AVg. VOLUMeD

STOCk HIgHlIgHTS

As of 7/31/13

HOldER BMO Asset Management Corp. 8.82%T. Rowe Price Associates, Inc. 8.77%BlackRock Fund Advisors 5.79%First Manhattan Co. 5.77%The Vanguard Group, Inc. 5.68%Dimensional Fund Advisors, Inc. 5.38%Red Rocks Capital LLC 4.38%F&C Asset Managers Ltd. 3.16%William Blair & Co. LLC (Investment Management) 3.09%Putnam Investment Management LLC 3.08%Waddell & Reed Investment Management Co. 2.41%Granahan Investment Management, Inc. 1.86%SSgA Funds Management, Inc. 1.69%Northern Trust Investments 1.49%Cubic Asset Management LLC 1.34%

TOp INSTITuTIONAl HOldERS

% OuTSTANdINg SHARES

WHy OWN SAFEguARd SCIENTIFICS (NySE:SFE)?

Full Value Yet to be Realized

Ownership Stakes in Exciting Partner Companies

Top Performance of Proven Team

Financial Strength, Flexibility and Liquidity

Strong Alignment of Interests

TECHNOlOgy

HEAlTHCARE

$197.3M

$250M - $270MRANGE

$142.7M

$50.1M$66.9M

$109.4M

2009ACTUAL

2010ACTUAL

2008ACTUAL

2011ACTUAL

2012ACTUAL

2013GUIDANCE

* Aggregate revenue guidance for 2013 and prior years, presented above, reflects revenue on a net basis. Revenue figures utilized for certain companies pertain to periods prior to Safeguard’s involvement with said companies and based solely on information provided to Safeguard by such companies. Safeguard reports the revenue of its equity and cost method partner companies on a one-quarter lag basis.

Safeguard Scientifics (NySE:SFE) provides growth capital and operational support to innovative healthcare and technology companies. Leveraging our team’s depth of strategic and operational expertise, we help entrepreneurs accelerate growth and build

long-term value in their businesses.

Our strong reputation and proven track record enable us to generate better deal

flow, attract accomplished entrepreneurs and top syndication partners, and gain access to the management and boards of Fortune 500 companies for various strategic

and M&A opportunities.

A Catalyst for Value Creation.

PARTNERCOMPANYAggREgATE REVENuE*

1953: Year Founded

1967: Safeguard IPO

100+ M&A Transactions

FAST FACTS

20+ IPOs

$372 MIllION Deployed Since 2006

$647 MIllION Realized Since 2006

twitter.safeguard.com youtube.safeguard.com

facebook.safeguard.com

©2013 Safeguard Scientifics, Inc. All rights reserved. All data current as of June 30, 2013 unless otherwise noted. The statements contained in this fact sheet that are not historical facts are forward looking statements which involve risk and uncertainties described in Safeguard’s filings with the Securities Exchange Commission.

Safeguard Scientifics, Inc. 435 Devon Park Drive, Building 800 Wayne, PA 19087P 610-293-0600 F 610-293-0601

www.safeguard.com linkedin.safeguard.com

slideshare.safeguard.com

blog.safeguard.com

FOllOW uS

stocktwits.safeguard.com

Stephen T. Zarrilli President and CEO

Brian J. Sisko EVP and Managing Director – Strategy, Development and Operations

Jeffrey B. Mcgroarty SVP and CFO

gary J. kurtzman, Md Managing Director, Healthcare

philip d. Moyer Managing Director, Technology

Erik B. Rasmussen Managing Director, Technology

John E. Shave III VP, Business Development and Corporate Communications

lEAdERSHIp TEAM

Innovationx(Capital+Expertise) = Results

SAFEguARd’S FORMulA FOR REAlIZINg VAluE

Healthcare Companies

Technology Companies

% Represents SafeguardOwnership on a Primary Basis

The continued success of our partner companies proves the effectiveness of Safeguard’s clear operational focus and patient capital approach. Safeguard has deployed $233 million in our current partner companies.

pARTNER COMpANIES

John E. Shave III

p 610.975.4952

E jshave@safeguard.com

A 435 Devon Park Drive Building 800 Wayne PA 19807

upCOMINg EVENTS IR CONTACT

September 2013

Rodman & Renshaw 15th Annual global Investment Conference New York, NY

October 2013

Safeguard Investor day New York, NY

Ascendiant Capital Markets, llC Edward Woo, CFA949.259.4932 Rating: Buy. Target Price: $20/share

CJS Securities Arnold Ursaner914.287.7600 Rating: Market Outperform. Target Price: $22/share

First Analysis Securities Corporation James Macdonald312.258.7124 Rating: Overweight.

kBW Troy Ward314.342.2714 Greg Mason314.342.2194 Rating: Outperform. Target Price: $21.50/share

puBlISHINg ANAlySTS

DEVELOPMENTSTAGE COMPANIES

INITIAL REVENUESTAGE COMPANIES

EXPANSIONSTAGE COMPANIES

HIGH TRACTIONSTAGE COMPANIES

17%

35%

28%

30%

40%

13%

38%

23%35%

30%

25%

49% 35%25%

44%

7%

28%

40% 23% 22%

pre-Revenue up to $5M in Revenue

$5M - $20M in Revenue

$20M+ in Revenue